[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100470454":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":30,"locations":38,"responsibleParty":72,"collaborators":74,"id":77,"slug":25,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":78,"sex":84,"minAge":85,"maxAge":25,"enrollmentInfo":86,"targetDuration":25,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":25,"overallStatus":41,"whyStopped":25,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Kantonsspital Winterthur KSW","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"SBRT with 9 Gy x 3 fractions to the treatment site.","EXPERIMENTAL","Patients will be treated with SBRT delivering 9 Gy x 3 fractions (BED10: 51.3 Gy) to the treatment site.",[13],"Radiation: SBRT",{"label":15,"type":16,"description":17,"interventionNames":18},"SBRT with 7 Gy x 5 fractions to the treatment site","ACTIVE_COMPARATOR","Patients will be treated with SBRT delivering 7 Gy x 5 fractions (BED10: 59.5 Gy) to the treatment site.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"RADIATION","SBRT","Stereotactic multiple fraction radiotherapy",[15,9],null,[27],{"name":28,"affiliation":5,"role":29},"Robert Foerster, MD","PRINCIPAL_INVESTIGATOR",[31,35],{"name":28,"role":32,"phone":33,"phoneExt":25,"email":34},"CONTACT","+4152 266 21 21","robert.foerster@ksw.ch",{"name":36,"role":32,"phone":33,"phoneExt":25,"email":37},"Nidar Batifi, RN","nidar.batifi@ksw.ch",[39,60],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Kantonsspital Winterthur","RECRUITING","Winterthur","Canton of Zurich","8401","Switzerland",{"type":47,"coordinates":48},"Point",[49,50],8.72413,47.50564,{"lat":50,"lon":49},[53,54,56,57],{"name":28,"role":32,"phone":33,"phoneExt":25,"email":34},{"name":36,"role":32,"phone":55,"phoneExt":25,"email":37},"+41052 266 21 21",{"name":28,"role":29,"phone":25,"phoneExt":25,"email":25},{"name":58,"role":59,"phone":25,"phoneExt":25,"email":25},"Christina Schroeder, MD","SUB_INVESTIGATOR",{"facility":61,"status":41,"city":62,"state":25,"zip":63,"country":45,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"University Hospital Bern","Bern","3010",{"type":47,"coordinates":65},[66,67],7.44744,46.94809,{"lat":67,"lon":66},[70],{"name":71,"role":32,"phone":25,"phoneExt":25,"email":25},"Hossein Hemmatazad, MD",{"type":73,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[75],{"name":76,"class":6},"Krebsforschung Schweiz, Bern, Switzerland","100470454",false,"NCT05406063","Stereotactic Multiple Fraction Radiotherapy for Non-spine Bone Metastases","Stereotactic Multiple Fraction Radiotherapy for Non-spine Bone Metastases a Multicentre Prospective, Open Label, Randomised Controlled Phase 3 Non-inferiority Clinical Trial","SMILE","Inclusion Criteria:\n\n* Personally signed and dated written informed consent,\n* Histological diagnosis of malignancy,\n* Histologically or radiologically diagnosed bone metastasis,\n* Age ≥ 18 years\n* Pain or under pain control medication\n\nExclusion Criteria:\n\n* Pregnant or lactating women,\n* Women of childbearing potential or sexually active males not willing to use effective contraception while on treatment and 3 months after the end of treatment,\n* Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc.,\n* Prior radiotherapy to the intended treatment site,\n* Lesions \\> 5cm in maximum diameter,\n* Prior treatment with radioactive isotopes within 30 days of randomisation,\n* Spinal column, hands, feet, or head as intended treatment site,- Fracture at the intended treatment site,\n* Surgery required or previous surgery at the intended treatment site\n* Instability of the intended treatment site.","ALL","18 Years",{"count":87,"type":88},162,"ESTIMATED","INTERVENTIONAL",[91],"NA","To investigate, whether multi-fraction stereotactic body radiation therapy (SBRT) within 3 treatment fractions is non-inferior to the current standard of care of 5 fraction SBRT regarding pain response at 3 months after radiotherapy.",[94,95,96],"Radiation Therapy","Bone Metastases","Pain","2025-05-19",{"date":99,"type":100},"2025-05-22","ACTUAL",{"date":102,"type":100},"2022-06-01",{"date":104,"type":88},"2026-05-31",{"name":5,"class":6},2]